ArticleThe Journal of general virology2025
The novel human astrovirus VA1 requires the proteasome during cell entry.
Article in The Journal of general virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Distinct intracellular and extracellular maturation of goose astrovirus 2 capsid protein and the potential of virus-like particles as a novel subunit vaccine.Frontiers in veterinary science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Astroviruses are important aetiological agents of gastroenteritis. Recently, two novel human astrovirus (HAstV) clades, VA and MLB, have been identified. However, the replication cycle of these viruses remains poorly characterized. Among these, the novel astrovirus VA1 has been of particular interest due to its reported association with neurological disease in immunocompromised patients. Previous studies have demonstrated that a functional proteasome is essential for the efficient replication of classic HAstVs. In this study, we investigated the role of the proteasome in the replication of HAstV-VA1. We assessed the impact of two proteasome inhibitors, MG132 and bortezomib, on viral replication. Both inhibitors significantly reduced viral protein and infectious progeny production in a dose-dependent manner. Our findings indicate that the inhibitory effects of these compounds are mediated through a mechanism affecting virus entry and a post-entry step in the viral replication cycle during the virus replication cycle.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.